ESPERION THERAPEUTICS INC (ESPR) Stock News

USA - NASDAQ:ESPR - US29664W1053 - Common Stock

2.96 USD

-0.07 (-2.31%)

Last: 11/13/2025, 8:00:02 PM

2.98 USD

+0.02 (+0.68%)

Pre-Market: 11/14/2025, 5:31:13 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ESPR Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: Chartmill

News Image

Esperion Therapeutics Inc (NASDAQ:ESPR) Reports Mixed Q3 2025 Results with Revenue Beat and Wider Loss

4 days ago - By: Esperion Therapeutics, Inc.

Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025

7 days ago - By: Zacks Investment Research - Mentions: RDY ANIP ARQT

ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down

8 days ago - By: Esperion Therapeutics, Inc.

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

8 days ago - By: Esperion Therapeutics, Inc.

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

8 days ago - By: Benzinga - Mentions: AMSC AOSL VAC ACHC ...

DoorDash Posts Downbeat Q3 Earnings, Joins elf Beauty, Duolingo, HubSpot And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

8 days ago - By: Benzinga - Mentions: STVN PODD AMRK SOLV ...

Earnings Scheduled For November 6, 2025

8 days ago - By: Esperion Therapeutics, Inc.

Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update

8 days ago - By: Esperion Therapeutics, Inc.

Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update

10 days ago - By: Esperion Therapeutics, Inc.

Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

10 days ago - By: Esperion Therapeutics, Inc.

Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

11 days ago - By: Esperion Therapeutics, Inc.

Esperion to Participate in Jefferies Global Healthcare Conference - London

17 days ago - By: Esperion Therapeutics, Inc.

Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET.

17 days ago - By: Esperion Therapeutics, Inc.

Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET.

18 days ago - By: Esperion Therapeutics, Inc.

Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025

18 days ago - By: Esperion Therapeutics, Inc.

Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025

22 days ago - By: Esperion Therapeutics, Inc.

Esperion to Report Third Quarter 2025 Financial Results on November 6

a month ago - By: Zacks Investment Research - Mentions: ANIP EVO CMMB

ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up

a month ago - By: Esperion Therapeutics, Inc.

Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis

a month ago - By: Esperion Therapeutics, Inc.

Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis

a month ago - By: Stocktwits

News Image

Why Is Esperion Therapeutics Stock Sinking Premarket Today?

a month ago - By: Esperion Therapeutics, Inc.

Esperion Announces Pricing of Public Offering of Common Stock

a month ago - By: Esperion Therapeutics, Inc.

Esperion Announces Pricing of Public Offering of Common Stock

a month ago - By: Esperion Therapeutics, Inc.

Esperion Announces Proposed Public Offering of Common Stock

a month ago - By: Esperion Therapeutics, Inc.

Esperion Announces Proposed Public Offering of Common Stock

a month ago - By: Stocktwits - Mentions: IWMW URTY

News Image

Esperion Shares Rally After Patent Litigation Settlement For Cholesterol Drugs

a month ago - By: Esperion Therapeutics, Inc.

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040

a month ago - By: Esperion Therapeutics, Inc.

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040

2 months ago - By: Esperion Therapeutics, Inc.

Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia